Overview

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)

Status:
Withdrawn

Trial end date:
2018-08-01

Target enrollment:

Participant gender:

Summary

This study is being conducted to evaluate the efficacy and safety/tolerability of SCH 900222/MK-3222 in a population of participants with moderate-to-severe plaque psoriasis.

Phase:

Phase 3

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.
Sun Pharma Global FZE
Sun Pharmaceutical Industries Limited

Treatments:

Etanercept